Prognostic utility of copy number variations in circulating tumor DNA in head and neck cancer.

Edward S Sim^1,2, Daniel A Ruiz-Torres^1,2,3, Pan Du⁴, Yong Huang⁴, Frank Zhang⁴, Shidong Jia⁴, Adam S Fisch⁵, Ross D Merkin^6,7, Jonathan J Paly⁸, Daniel L Faden^1,2,3

¹Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, USA.

²Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.

³Broad Institute of MIT and Harvard, Cambridge, MA, USA.

⁴Predicine, Hayward, CA, USA.

⁵Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

⁶Department of Medicine, Harvard Medical School, Boston, MA, USA.

⁷Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA.

⁸Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Plasma circulating tumor DNA (ctDNA) is a minimally invasive biomarker in head and neck squamous cell carcinoma (HNSCC). Most commercially available assays for human papillomavirus-unrelated HNSCC are tumor-informed assays that require tissue sampling and may not comprehensively capture tumor heterogeneity. We evaluated a tumor-agnostic approach using genome-wide ctDNA copy-number vari…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.